Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Parallel Group, Single Dose Study to Investigate the PK and Safety of Belimumab 200 mg Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Participants
Conditions
Interventions
Belimumab for IV
Belimumab for SC
Locations
1
China
GSK Investigational Site
Shanghai, China
Start Date
October 28, 2019
Primary Completion Date
January 14, 2020
Completion Date
January 14, 2020
Last Updated
December 28, 2020
NCT06647069
NCT07371468
NCT06333483
NCT07219563
NCT06875960
NCT07413341
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions